Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Hepion Pharmaceuticals And Neoleukin Therapeutics: 2 Micro-Cap Pharmaceutical Stocks Priced For 'Non Success' With Promising Drugs

Shares of Hepion Pharmaceuticals Inc (NASDAQ: HEPA), formerly ContraVir Pharma, are ripping higher after the thinly-traded, nano-cap biotech announced results from an animal study of its lead product candidate CRV431.

Hepion Rips Higher After NASH Drug Confirms Antifibrotic Activity In Animal Study

Shares of Hepion Pharmaceuticals Inc. rocketed 57% in active trading to pace all premarket gainers, after the biopharmceutical company announced positive results from a preclinical study of its CRV431 liver cirrhosis treatment.

Hepion Pharmaceuticals' stock rockets after upbeat results of preclinical study of liver cirrhosis treatment

Virtus LifeSci Biotech Clinical Trials ETF

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

ALPS Medical Breakthroughs ETF

The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.

Biotech ETFs Surge on a Flurry of Positive News

Shares of Hepion Pharmaceuticals Inc. HEPA, -4.94% soared 45% in very active premarket trading Thursday, after the biopharmaceutical company published data showing potential for its CRV431 to be a drug candidate for liver disease treatment.

Hepion Pharmaceuticals stock soars premarket-leading volume after positive data on liver disease treatment

News for Hepion Pharmaceuticals Inc Stock (HEPA)